Exchange Traded Concepts LLC Buys 67,375 Shares of Dynavax Technologies Corporation $DVAX

Exchange Traded Concepts LLC raised its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 50.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 200,976 shares of the biopharmaceutical company’s stock after acquiring an additional 67,375 shares during the period. Exchange Traded Concepts LLC’s holdings in Dynavax Technologies were worth $1,996,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in DVAX. Marshall Wace LLP lifted its position in shares of Dynavax Technologies by 107.2% during the second quarter. Marshall Wace LLP now owns 1,814,934 shares of the biopharmaceutical company’s stock valued at $18,004,000 after purchasing an additional 939,076 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in Dynavax Technologies by 237.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 656,541 shares of the biopharmaceutical company’s stock valued at $8,515,000 after buying an additional 461,980 shares during the last quarter. Man Group plc lifted its position in shares of Dynavax Technologies by 925.5% during the 2nd quarter. Man Group plc now owns 447,847 shares of the biopharmaceutical company’s stock worth $4,443,000 after buying an additional 404,175 shares in the last quarter. Woodline Partners LP boosted its stake in shares of Dynavax Technologies by 48.4% in the 1st quarter. Woodline Partners LP now owns 1,178,763 shares of the biopharmaceutical company’s stock worth $15,289,000 after buying an additional 384,288 shares during the last quarter. Finally, Squarepoint Ops LLC grew its holdings in shares of Dynavax Technologies by 222.3% in the second quarter. Squarepoint Ops LLC now owns 435,577 shares of the biopharmaceutical company’s stock valued at $4,321,000 after acquiring an additional 300,421 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

Dynavax Technologies stock opened at $15.38 on Friday. The firm has a market capitalization of $1.81 billion, a P/E ratio of -41.57 and a beta of 0.89. Dynavax Technologies Corporation has a one year low of $9.20 and a one year high of $15.49. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94. The business has a fifty day moving average price of $11.10 and a 200-day moving average price of $10.58.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%.The business had revenue of $94.88 million for the quarter, compared to analysts’ expectations of $94.00 million. As a group, equities research analysts forecast that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on DVAX shares. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, William Blair downgraded shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a report on Wednesday. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Dynavax Technologies presently has a consensus rating of “Hold” and a consensus target price of $24.33.

Dynavax Technologies Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.